Vijaya Diagnostic appoints Narasimha Raju K.A. as Chief Financial Officer

Management Changes View source PDF Explain this filing

VIJAYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹1379.40

prior close

₹1399.00

announcement price

After-mkt

timing

Nifty Smallcap 250market+1.4%-0.7% vs market

Healthcare Service Provider peers, median of 24sector+0.3%+0.4% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Smallcap 250 and 0.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.5

10m

-2.3

15m

-1.6

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+1.4-0.7+0.3+0.4

Next day

+0.8+1.7-0.9+0.7+0.1

+0.3+0.6-0.2-0.8+1.1

+0.7+1.2-0.5-0.7+1.5

+4.0+1.3+2.7-1.3+5.3

-2.6+0.7-3.3-1.7-0.9

-3.3+1.3-4.6-0.9-2.5

15d

-2.2+0.2-2.5-1.5-0.7

+1.2+2.6-1.5-1.4+2.6

+9.0+3.1+5.8-0.7+9.7

+5.1-0.6+5.7-6.1+11.2

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vijaya Diagnostic Centre has appointed Mr. Narasimha Raju K.A. as Chief Financial Officer with effect from July 9, 2026. He is a Chartered Accountant with over 20 years of experience spanning Big Four audit (S R Batliboi and Co, an EY affiliate), healthcare, diagnostics, and renewable energy. He previously served as CFO of the same company from March 2021 to March 2025, leading the IPO during COVID-19, and most recently was CFO at Yashoda Group of Hospitals. His expertise covers investor relations, M&A, Ind AS/IFRS reporting, governance, and capital market transactions.

Likely market impact

Continuity at the top finance role as a familiar face returns, likely to reinforce financial discipline and governance. Neutral to mildly positive for shareholders.